Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Investor Presentation (June 2025)
41 slides from Indivior Pharmaceuticals's investor presentation, June 2025
Slide 1: Investor Presentation June 2025
Investor Presentation June 2025 For Investor Relations Purposes Only
Slide 2: Important Cautionary Statement Regarding Forward-looking Statements
INVESTOR PRESENTATION | JUNE 2025 Important Cautionary Statement Regarding Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding expected future cash flows; t
Slide 3: Founded to Help Address the Opioid Crisis
INVESTOR PRESENTATION | JUNE 2025 Founded to Help Address the Opioid Crisis Leading with Science Financial Strength • Leading in discovery and commercialization of buprenorphine evidence-based • $1,188m total net revenue (NR) (FY2024) medicines for opioid dependence for over 30 years • $320m Non-GAA
Slide 4: Track Record of Strong Net Revenue Growth
INVESTOR PRESENTATION | JUNE 2025 Track Record of Strong Net Revenue Growth Revenue Growth Driven by the U.S.… …And Increasing Contribution from SUBLOCADE $1,188m $1,188m $1,093m $1,093m $901m $1,008m $901m $791m $912m $791m $647m $732m $647m $756m $603m $630m $456m $408m $244m $130m 2020 2021 2022
Slide 5: Clear Path to Generating Meaningful Cash Flows from Operations
INVESTOR PRESENTATION | JUNE 2025 Clear Path to Generating Meaningful Cash Flows from Operations Leverage Cost Structure… … To Drive Robust Bottom-line Growth $679m $651m $533m $320m $462m $477m $274m2 $220m $188m 71% 27% 59% 59% 60% 57% 24% 24% 25% $88m 14% 2020 2021 2022 2023 2024 2020 2021 2022 2
Slide 6: U.S. Commercial Portfolio Spanning Recovery and Rescue
INVESTOR PRESENTATION | JUNE 2025 U.S. Commercial Portfolio Spanning Recovery and Rescue Recovery Medicines Rescue Medicine Durable Growth Driver with Genericized Market Strong Patent Protection Strong Patent Protection IP Protection 12 Orange Book patents 2 Orange Book patents Genericized (2031 – 2
Slide 7: 2025: A Transition Year
INVESTOR PRESENTATION | JUNE 2025 2025: A Transition Year Foundational Leadership Additions Current U.S. Dynamics 2025 U.S. NR Headwinds: Strengthening expertise and leadership with Board of • SUBLOCADE NR impacted by funding gaps in the Criminal Justice Directors (BOD) and Executive Team additions
Slide 8: Transition Year Focus
INVESTOR PRESENTATION | JUNE 2025 Transition Year Focus Deliver 2025 Operating Plan Grow SUBLOCADE Advance the OUD Pipeline Strengthen the Balance Sheet 7
Slide 9: SUBLOCADE
= INDIVIOR SUBLOCADE”
Slide 10: Bipartisan Commitment to Addressing Opioid Crisis in the U.S.
INVESTOR PRESENTATION | JUNE 2025 Bipartisan Commitment to Addressing Opioid Crisis in the U.S. U.S. Illicit Opioid Use Could c Times Higher Than Be 20 AGED c Opioid Overdoses Remain the Leading May 12, 2025 Previously Estimated May 14, 2025 18-44 Cause of Death WTAS: Widespread Industry Support of
Slide 11: LAI Buprenorphine Medications are Under-Penetrated in the Treatment of OUD
INVESTOR PRESENTATION | JUNE 2025 LAI Buprenorphine Medications are Under-Penetrated in the Treatment of OUD Current 7% LAI usage in BMAT population allows for significant potential expansion 8.9m1 Misuse opioids in U.S. (Total Addressable Market) 5.9m1 OUD diagnosed in U.S. (Service Addressable Mar
Slide 12: American Society of Addiction Medicine (ASAM) BMAT Guidelines
INVESTOR PRESENTATION | JUNE 2025 American Society of Addiction Medicine (ASAM) BMAT Guidelines ASAM Clinical Guideline1 ASAM Clinical Consideration1,2 Treatment Goals with Buprenorphine1 For Individuals using High-Potency Synthetic Opioids (HPSO) Suppress opioid Stop or Reduce Engage patients withd
Slide 13: ≥2 ng/mL Buprenorphine Blood Plasma Levels are Needed to Help Protect Most Patients
INVESTOR PRESENTATION | JUNE 2025 ≥2 ng/mL Buprenorphine Blood Plasma Levels are Needed to Help Protect Most Patients from Opioid-Rewarding Effects1,2 As buprenorphine plasma levels increase, the number of receptors available for opioids decreases, resulting in a decrease in opioid-rewarding effects
Slide 14: SUBLOCADE Delivers Continuous, Long-Lasting Protection with 43 to 60 Day Half-Life
INVESTOR PRESENTATION | JUNE 2025 SUBLOCADE Delivers Continuous, Long-Lasting Protection All Month with a 43 to 60 Day Half-Life1,2,3 Mean Buprenorphine Levels During TM* BUP Induction, Mean Weekly Buprenorphine Concentrations5,6 Dose-Stabilization, and After the First 2 Injections of SUBLOCADE4 • A
Slide 15: Longer SUBLOCADE Treatment Shown to Improve Patient Outcomes
INVESTOR PRESENTATION | JUNE 2025 Longer SUBLOCADE Treatment Shown to Improve Patient Outcomes 75% Continuous 12-month self-reported abstinence if subjects stayed on SUBLOCADE for 12 months 80% 70% The longer the SUBLOCADE 75.0% % Abstinent subjects 60% treatment duration, the higher the likelihood
Slide 16: SUBLOCADE Helps Transform Recovery
INVESTOR PRESENTATION | JUNE 2025 SUBLOCADE Helps Transform Recovery SUBLOCADE Offers Month Long Continuous Protection from Opioid-Rewarding Effects Continuous Protection Long-Lasting Reliable From the Start Effects Dosing ● Effective blockade from day 1 – the ● Longest half-life (43-60 days) of ● S
Slide 17: New SUBLOCADE Label Benefits
INVESTOR PRESENTATION | JUNE 2025 New SUBLOCADE Label Benefits Label Updates Further Differentiate SUBLOCADE for Today’s Opioid Crisis Driven by the Proliferation of Synthetic Opioids START PATIENTS ON SUBLOCADE SOONER: Only monthly CLINICALLY RELEVANT: Rapid initiation studied in majority fentanyl
Slide 18: Strong Fundamentals Position SUBLOCADE for Growth
INVESTOR PRESENTATION | JUNE 2025 Strong Fundamentals Position SUBLOCADE for Growth Growing SUBLOCADE Prescriber Base1 10,665 Prescribing Depth Improving: 5,277 8,768 HCPs with 5+ SUBLOCADE Patients1 4,358 6,322 3,047 4,475 3,255 1,870 1,186 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 Broad Pa
Slide 19: SUBLOCADE U.S. Commercial Focus
INVESTOR PRESENTATION | JUNE 2025 SUBLOCADE U.S. Commercial Focus GOAL: GOAL: SUBLOCADE as #1 LAI Choice LAI First Line in All Care Settings Enhanced competitiveness across all key channels Activate patients through direct-to-consumer (DTC) campaign Driving broad, rapid HCP awareness of new label be
Slide 20: OPVEE
15, <INDIVIOR
Slide 21: Potent Synthetic Opioids (Fentanyl) are Driving U.S. Overdose Crisis
INVESTOR PRESENTATION | JUNE 2025 Potent Synthetic Opioids (Fentanyl) are Driving U.S. Overdose Crisis Contribution of Synthetic Opioids to ~26m People in the U.S. are All Opioid Overdose Deaths Potentially Misusing Synthetic Opioids 1 0.9 Illicit Fentanyl Use in the U.S. (% population) 0.8 90% in 2
Slide 22: OPVEE Provides Rapid, Potent, Long-Lasting Reduction of Respiratory Depression
INVESTOR PRESENTATION | JUNE 2025 OPVEE Provides Rapid, Potent, Long-Lasting Reduction of Respiratory Depression1 to Address the Current Wave of Synthetic Opioid Overdoses Triple Threat of Synthetic Opioid Pharmacology such as Fentanyl Rapid Potent Long-Lasting • The first and only nasal rescue medi
Slide 23: Scientific Evidence Confirms OPVEE's Potential to Improve and Sustain Reversal of an Opioid Overdose
INVESTOR PRESENTATION | JUNE 2025 Scientific Evidence Confirms OPVEE’s Potential to Improve and Sustain Reversal of an Opioid Overdose OPVEE compared with 4mg nasal naloxone OPVEE vs. 4mg nasal naloxone(5) OPNT0003 (3mg) Naloxone (4mg) Affinity at μ opioid receptors 1.0 (1) 5.4 (1) Plasma concentrat
Slide 24: Pipeline
YEARS OF ae INDIVIOR
Slide 25: OUD Focused Pipeline
INVESTOR PRESENTATION | JUNE 2025 OUD Focused Pipeline Trial Patients & Population Design Primary Endpoints Estimated Completion INDV-6001 Evaluate PK, safety and 3-month long-acting 122 Patients Multiple dose tolerability of INDV-6001 Last Patient Last Visit buprenorphine Phase II PK study followin
Slide 26: Financials
1s6in INDIVIOR
Slide 27: Capital Markets Footprint to Align with U.S. Focused Business
INVESTOR PRESENTATION | JUNE 2025 Capital Markets Footprint to Align with U.S. Focused Business Transition from London Stock Exchange (LSE) to Nasdaq May 23rd June 30th July 25th June 2nd July 24th Russell U.S. Equity Indexes Anticipate Inclusion in Russell U.S. All Trading on Nasdaq Under LSE Delis
Slide 28: On Track to Achieve FY 2025 Guidance
INVESTOR PRESENTATION | JUNE 2025 On Track to Achieve FY 2025 Guidance – Reaffirmed April 24, 20251 Q1 2025 Results 2025 Financial Guidance Q1 2025 Total Net Revenue (NR) $266m $955 - $1,025m Key Financial Themes SUBLOCADE NR2 $176m $725 - $765m • Overall Q1 2025 results in-line with FY 2025 guidanc
Slide 29: Transition Year: Evolution of the Business in 2025
INVESTOR PRESENTATION | JUNE 2025 Transition Year: Evolution of the Business in 20251 SUBLOCADE Contribution to Expect ~$60m in Non-GAAP Total NR Expected to Increase Operating Expense Savings4 ~$60m reduction 25% $679m 36% $618M 2024 2025E2 $103m $88m 64% 75% $576m $530m 2024 2025E SUBLOCADE net re
Slide 30: Generating Significant Cash Flow with Strong Balance Sheet
INVESTOR PRESENTATION | JUNE 2025 Generating Significant Cash Flow with Strong Balance Sheet Growing Non-GAAP EBITDA1 Key Balance Sheet Items $360m $400m of cash and investments as of Q1 2025 $252m $214m $350m term loan maturing in 2030 with $50m revolving credit facility $144m $148m* provides finan
Slide 31: Transition Year Focus
INVESTOR PRESENTATION | JUNE 2025 Transition Year Focus Deliver 2025 Operating Plan Grow SUBLOCADE Advance the OUD Pipeline Strengthen the Balance Sheet 30
Slide 32: Appendix
Appendix Latosha Regional Head of U.S.Medical Affairs-West, Indian Health Services Medical Lead
Slide 33: Q1 2025 Financial Highlights
INVESTOR PRESENTATION | JUNE 2025 Q1 2025 Financial Highlights OPERATING RESULTS: (REPORTED AND NON-GAAP1) KEY TAKEAWAYS: (VS Q1 2024 UNLESS OTHERWISE INDICATED) $ mil Q1 2025 Q1 2024 Change Total NR decline of 6% (5% at constant FX): Net Revenue (NR): $266 $284 (6)% • U.S. NR down 8%; lower SUBOXON
Slide 34: Q1 2025 Financial Reconciliations
INVESTOR PRESENTATION | JUNE 2025 Q1 2025 Financial Reconciliations1 Three Months Ended March 31, Q1 2025 Q1 2024 GAAP selling, general and administrative expenses $ 132 $ 143 Adjustments within SG&A Corporate Initiative Transition1 2 0 Acquisition-related costs2 — 2 Less: Adjustments in selling, ge
Slide 35: FY 2020–2024 Non-GAAP Operating Income Reconciliations
INVESTOR PRESENTATION | JUNE 2025 FY 2020–2024 Non-GAAP Operating Income Reconciliations Reconciliation of Net Income to Non-GAAP Operating Income ($m) GAAP------------------------------- IFRS------------------- 2024 2023 2022 2021 2020 Net Income 7 (126) (42) 205 (148) Net Finance Income (23) (43)
Slide 36: FY 2020–2024 Non-GAAP Operating Expense Reconciliations
INVESTOR PRESENTATION | JUNE 2025 FY 2020–2024 Non-GAAP Operating Expense Reconciliations Reconciliation of Non-GAAP operating expenses GAAP-------------------------------- IFRS-------------------- 2024 2023 2022 2021 2020 Total Operating Expenses, net 919 1,072 827 451 706 Other operating expense (
Slide 37: FY 2020–2025 Q1 EBITDA Reconciliations
INVESTOR PRESENTATION | JUNE 2025 FY 2020–2025 Q1 EBTIDA Reconciliations Reconciliation of EBITDA GAAP----------------------------------------------IFRS--------------------- Q1 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Income 47 7 (126) (42) 205 (148) Add Back: Interest Income (4) (23) (43) (
Slide 38: FY 2024 Leverage Reconciliation
INVESTOR PRESENTATION | JUNE 2025 FY 2024 Leverage Reconciliation Reconciliation of Leverage Ratio GAAP FY 2024 Total Gross Debt 350 Operating Income 38 Leverage Ratio 9.2 Non-GAAP adjustments in Operations 281 Dep/Amort (excluding ROU Amort) 17 Share-Based Compensation Expense 24 Total Adjustments
Slide 39: Global Markets
INVESTOR PRESENTATION | JUNE 2025 Global Markets SUBLOCADE (SUBUTEX®PR (ROW)) SUBOXONE Film1 Net Revenue by Geography FY 2024 North U.S. ● ● America Canada ● ● France ● ● Italy ● ● 85% Germany ● ● ● ● $1,188m Denmark, Norway2 Europe & Middle East Sweden ● ● 15% Finland ● ● Switzerland ● UK ● ● Israe
Slide 40: SUBLOCADE Indication and Highlighted Safety Information
INVESTOR PRESENTATION | JUNE 2025 SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use (CIII) INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphi
Slide 41: OPVEE Indication and Highlighted Safety Information
INVESTOR PRESENTATION | JUNE 2025 OPVEE® (nalmefene) nasal spray INDICATION AND USAGE OPVEE nasal spray is an opioid antagonist indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as ma